Quest Diagnostics (DGX) Stock Could Be Cheap Despite A 105% Run

Quest Diagnostics has delivered a strong share price run in recent years, and that raises a simple question for you as an investor: Is the current US$235.00 price tag still in line with the cash the business is expected to generate?

• Over the past 3 years the stock has returned 104.8%, which puts real pressure on the idea that its cash flows alone can carry the current valuation.
• The group’s lab testing model can convert a large share of revenue into cash, so any change in volume trends or pricing power may have a direct impact on the cash flow stream that underpins today’s share price.
• What if you looked at Quest Diagnostics through its earnings instead? See why Quest Diagnostics's 24.5x P/E tells a different valuation story.

The issue now is whether Quest Diagnostics’ recent share price performance is adequately supported by the cash flows implied by its intrinsic value estimate using the Discounted Cash Flow (DCF) approach.

If you are weighing Quest Diagnostics against other ways to play a cash flow focused thesis, it can help to line it up next to 33 high quality undervalued stocks for context.

Is Quest Diagnostics Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here looks at the cash Quest Diagnostics can return to shareholders over time and discounts it back to today. Latest twelve month free cash flow sits at about $1.4b, and the projections used in this 2 Stage Free Cash Flow to Equity approach assume that this cash generation continues to grow rather than shrink.

Those estimates feed into an intrinsic value range that, on the model’s numbers, comes out substantially above the current $235.00 share price. For you as an investor, the key point is that the DCF is built on moderate, steady free cash flow growth in dollar terms rather than dramatic swings. The outcome therefore relies more on how durable Quest Diagnostics’ cash engine proves to be than on heroic expansion assumptions. Find out what Quest Diagnostics could be worth using our Discounted Cash Flow (DCF) estimate.

The Quest Diagnostics Narrative: What Would Justify Today's Price?

Quest Diagnostics Narratives on Simply Wall St pick up where this valuation puzzle leaves off by spelling out what mix of future growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today’s price, and they live on the Community page. Each one links its valuation number to a clear view on how Quest Diagnostics' growth, profitability and risk profile might evolve, which you can track against fresh information over time.

One of the top community narratives on Quest Diagnostics: 5% undervalued

"The main factor that has to go right is that Quest Diagnostics continues to scale automation, AI tools, and lab productivity programs…"

Discover why this Narrative puts Quest Diagnostics at 5% undervalued.

Before acting on Quest Diagnostics' valuation, there is one more angle to check

The cash flow story only goes so far if the people steering Quest Diagnostics are not aligned with you, and how they are rewarded can tell you a lot about that alignment. See who runs Quest Diagnostics and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com